Travis Coy compensation by year
Immunocore Summary Compensation Table · the one fiscal year held| Component | FY2025 |
|---|---|
| Salary | $500,000 |
| Bonus | $100,000 |
| Stock awards | $0 |
| Option awards | $4,299,989 |
| Non-equity incentive | $250,000 |
| Pension and deferred compensation | $0 |
| All other | $21,220 |
| Total | $5,171,209 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Immunocore Holdings plc DEF 14A filed April 16, 2026, accession 0001140361-26-015122, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Immunocore Holdings plc filed document, accession 0001140361-26-015122. Every figure is read from that document and cited to the page and table it appears in. Filed April 16, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| Option | 274,033 | — | $29.50 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Immunocore Holdings plc's FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Change-in-control & termination
estimated payments Immunocore discloses, by trigger · FY2025| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Change in control and resignation for good reason | $750,000 | $1,427,712 | $55,184 | $2,732,896 |
| Resignation for good reason, no change in control | $500,000 | $0 | $36,789 | $536,789 |
Per the Potential Payments Upon Termination or Change in Control table in Immunocore Holdings plc's FY2025 proxy. Estimates as the company printed them; a dash means it printed no figure.
Immunocore’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Bahija Jallal | Chief Executive Officer | $10,885,268 |
| Travis Coy · this page | Chief Financial Officer and Head of Corporate Development | $5,171,209 |
| David Berman | Former Executive Vice President, Head of Research & Development | $4,278,988 |
| Tina St. Leger | Chief Human Resources Officer | $1,204,261 |
Board service
Immunocore board · FY2023–FY2025How this board is paid
Company policy: Immunocore pays directors a $50,000 cash retainer and $400,000 in equity. As stated in Immunocore's FY2025 proxy.
Travis Coy's compensation dossier, Immunocore
You have read Travis Coy's totals and holdings. The dossier adds each equity grant Immunocore disclosed for Travis Coy and Immunocore's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.
See an example →The full Immunocore compensation record
free company briefThis page is one person within Immunocore's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Immunocore proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Immunocore's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Immunocore's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order IMCR
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.